As we mark the opening of the new J&J Satellite Center for Global Health Discovery at the Duke–NUS Medical School (Duke-NUS) in Singapore, Johnson & Johnson Innovation, together with Johnson & Johnson Global Public Health, is proud to launch theGlobal Health Discovery QuickFire Challenge: Flavivirus Infections.Innovators from across the Asia Pacific and Oceania regions are invited to submit potentially ground-breaking ideas aiming to treat, control, or prevent flavivirus disease.
Flaviviruses are vector-borne RNA virusesthat can potentially cause a variety of severe diseases in humans, impacting an estimated 400 million people annually. Flaviviruses are often carried by arthropods such as ticks and mosquitoes, withmore than a quarter of the world’s populationliving in areas where mosquito-borne flaviviruses are considered endemic. There are currentlyno specific treatments available for flavivirus diseasesand few vaccines are available to prevent them, highlighting the need for novel therapies aiming to tackle these emerging health threats.
Johnson & Johnson is committed to helping address the dual gap in innovation and health equity through the establishment of the J&J Centers for Global Health Discovery (J&J CGHD). This global network of research partnerships brings together our talent and expertise with that of leading academic institutions with the aim to stimulate and speed up the early-stage research and development needed to address entrenched and emerging pandemic threats.
The launch of the J&J Satellite Center for Global Health Discovery at the Duke–NUS Medical School aims to advance scientific discoveries to help treat, control, or prevent flaviviruses with the goal of tackling the next global public health threat.
最好的创新者(s)潜在的解决方案will receive grant funding from a total pool of $300,000, access to the Johnson & Johnson Innovation - JLABS Asia Pacific community, including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts at the Johnson & Johnson Family of Companies.*
Apply athttp://jji.jnj/flavivirusby November 4, 2022.
The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.
* Subject to the execution of the necessary documentation and (award) agreements.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us atwww.jnjinnovation.com.
About the J&J Centers for Global Health Discovery
Johnson & Johnson is joining forces with renowned institutions and leveraging their regional networks with the aim to bolster innovation and health equity in parallel through the establishment of the J&J Centers for Global Health Discovery. The Satellite Centers will provide long-term opportunities for mentorship of emerging talent in the discovery sciences to stimulate both local innovation and capacity.
The risk of intense epidemics isgrowingrapidly, with the probability of novel disease outbreaks likely to increase three-fold in the coming decades. Despite this, the last decade has seen a consistentdeclinein funding for basic science. The J&J Centers are an important step in turning this tide and delivering innovations needed to address the diseases that disproportionately impact the world's poorest and most vulnerable people.
Johnson & Johnsonlaunchedthe first Satellite Center in July 2021 at the London School of Hygiene & Tropical Medicine (LSHTM), which is focused on developing cutting-edge science to build the next-generation of drug regimens needed to treat all forms of tuberculosis (TB). In 2022, Johnson & Johnson brought online two additional Satellite Centers, at the Holistic Drug Discovery and Development Centre at the University of Cape Town and at Duke-NUS Medical School, focusing on antimicrobial resistance and flaviviruses respectfully.
To learn more, visitjnj.com/global-public-health/discovery-centers.
